Arbutus Biopharma Corp financial data

Symbol
ABUS on Nasdaq
Industry
Pharmaceutical Preparations
Location
701 Veterans Circle, Warminster, PA
State of incorporation
British Columbia, Canada
Fiscal year end
December 31
Former names
TEKMIRA PHARMACEUTICALS CORP (to 8/3/2015), TEKMIRA PHARMACEUTICALS Corp (to 8/3/2015)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 651 % +13%
Debt-to-equity 32.3 % -7.88%
Return On Equity -68.2 % -20.8%
Return On Assets -51.6 % -23.3%
Operating Margin -1.23K % -243%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 189M shares +13%
Common Stock, Shares, Outstanding 189M shares +13%
Entity Public Float 288M USD -0.79%
Common Stock, Value, Issued 1.41B USD +4.58%
Weighted Average Number of Shares Outstanding, Basic 189M shares +12.8%
Weighted Average Number of Shares Outstanding, Diluted 189M shares +12.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 6.74M USD -69.7%
Research and Development Expense 62.8M USD -20.6%
General and Administrative Expense 22.5M USD +4.04%
Operating Income (Loss) -83.1M USD -4.02%
Nonoperating Income (Expense) 6.43M USD +44.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.1M USD -14.4%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -76.7M USD -1.63%
Earnings Per Share, Basic -0.43 USD/shares +4.44%
Earnings Per Share, Diluted -0.43 USD/shares +4.44%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.8M USD +81.7%
Cash, Cash Equivalents, and Short-term Investments 132M USD -28.2%
Accounts Receivable, after Allowance for Credit Loss, Current 1.61M USD -25.9%
Assets, Current 133M USD -6.24%
Property, Plant and Equipment, Net 3.56M USD -29.3%
Operating Lease, Right-of-Use Asset 1.14M USD -23.8%
Other Assets, Noncurrent 0 USD -100%
Assets 140M USD -11.5%
Liabilities, Current 18.9M USD -15.2%
Operating Lease, Liability, Noncurrent 978K USD -34.7%
Liabilities 33.6M USD -14.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -48.1M USD +1.62%
Retained Earnings (Accumulated Deficit) -1.33B USD -6.1%
Stockholders' Equity Attributable to Parent 107M USD -10.4%
Liabilities and Equity 140M USD -11.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.3M USD +29.3%
Net Cash Provided by (Used in) Financing Activities 24.4M USD +19.7%
Net Cash Provided by (Used in) Investing Activities 11.7M USD -29.9%
Common Stock, Shares, Issued 189M shares +13%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 16.8M USD +71.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 31.8M USD +81.7%
Deferred Tax Assets, Valuation Allowance 164M USD +12.7%
Operating Lease, Liability 1.77M USD -19.2%
Payments to Acquire Property, Plant, and Equipment 95K USD -18.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -75.9M USD -3.49%
Lessee, Operating Lease, Liability, to be Paid 2.04M USD -22.7%
Property, Plant and Equipment, Gross 16.6M USD +4.43%
Operating Lease, Liability, Current 468K USD +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 635K USD +3.08%
Lessee, Operating Lease, Liability, to be Paid, Year One 616K USD +3.01%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 271K USD -39.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 654K USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 89.1M USD +6.61%
Preferred Stock, Shares Authorized 1.16M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 134K USD -79.5%
Additional Paid in Capital 81.4M USD +2.36%
Depreciation, Depletion and Amortization 355K USD +6.29%
Share-based Payment Arrangement, Expense 9.08M USD -1.82%
Interest Expense 168K USD -84.8%